Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 20/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25367271 | 0.88 | ACSS2 (0.56) | ACSS2 | |
| SCHEMBL17263209 | 0.87 | ACSS2 (0.67) | ACSS2 | |
| SCHEMBL23843503 | 0.87 | ACSS2 (0.82) | ACSS2 | |
| SCHEMBL23843433 | 0.86 | ACSS2 (0.81) | ACSS2 | |
| SCHEMBL23843480 | 0.85 | ACSS2 (0.80) | ACSS2 | |
| SCHEMBL25367738 | 0.85 | ACSS2 (0.56) | ACSS2 | |
| SCHEMBL23843477 | 0.84 | ACSS2 (1.00) | ACSS2 | |
| SCHEMBL26046754 | 0.82 | ACSS2 (0.77) | ACSS2 | |
| SCHEMBL17263158 | 0.81 | ACSS2 (0.66) | ACSS2 | |
| SCHEMBL23843441 | 0.79 | ACSS2 (0.75) | ACSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271956-A1 | AMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-08-31 | — | — | US | claimed |
| EP-4121429-B1 | CONDENSED PYRIDINE DERIVATIVES SUBSTITUED BY AMIDE FUNCTIONS AS ACSS2 INHIBITORS | MERCK PATENT GMBH (DE) | 2025-08-13 | — | — | EP | disclosed |
| US-20230271956-A1 | AMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-08-31 | — | — | US | disclosed |
| US-20230271956-A1 | AMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-08-31 | — | — | US | disclosed |
| WO-2021185789-A1 | CONDENSED PYRIDINE DERIVASTIVES SUBSTITUED BY AMIDE FUNCTIONS AS ACSS2 INHIBITORS | MERCK PATENT GMBH (DE) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271956-A1 | AMIDE DERIVATIVES | BRCA1, HRAS, PCNA | ACSS2 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.